Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Intellia Therapeutics (NTLA) Receivables - Other (2016 - 2023)

Intellia Therapeutics (NTLA) has disclosed Receivables - Other for 9 consecutive years, with $1.0 million as the latest value for Q4 2023.

  • Quarterly Receivables - Other fell 37.5% to $1.0 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2023, down 37.5% year-over-year, with the annual reading at $1.0 million for FY2023, N/A changed from the prior year.
  • Receivables - Other for Q4 2023 was $1.0 million at Intellia Therapeutics, roughly flat from $1.0 million in the prior quarter.
  • The five-year high for Receivables - Other was $8.4 million in Q1 2020, with the low at $100000.0 in Q4 2021.
  • Average Receivables - Other over 5 years is $2.0 million, with a median of $1.0 million recorded in 2019.
  • The sharpest move saw Receivables - Other plummeted 95.24% in 2021, then skyrocketed 1500.0% in 2022.
  • Over 5 years, Receivables - Other stood at $3.6 million in 2019, then plummeted by 41.67% to $2.1 million in 2020, then tumbled by 95.24% to $100000.0 in 2021, then surged by 1500.0% to $1.6 million in 2022, then crashed by 37.5% to $1.0 million in 2023.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $1.0 million, $1.0 million, and $1.4 million for Q4 2023, Q3 2023, and Q2 2023 respectively.